fda warning compounding semaglutide october 2025 Drug compounders sue over declaration ending Wegovy shortage Digital pharmacy to offer weight-loss

Compounding outsourcing facilities play a big role in helping patients access the medications they need, although they come with potential risks such as: Contamination: Compounded semaglutide injections can be contaminated if not made in a sterile environment

No drug information sheet, no printed injection guidance, no temperature storage details

These common interactions involve two salt bridges with E 6.53b and E/D 7.42b (via the positively charged N-terminal nitrogen atom of Y1 P ), stacking interactions with W39 GLP-1R /W39 GIPR /W36 GCGR (via F22 P ), Y 1.43b (via F6 P ) and W 5.36b (via Y1 P ), multiple hydrogen bonds with L32 GLP-1R /A32 GIPR /M29 GCGR (via D15 P ), Y 1.43b (via Q3 P ), Y 1.47b (via Q3 P ), T/E 45.52b (via S11 P ) and N300 GLP-1R /N290 GIPR /N298 GCGR (via S8 P ), along with extensive hydrophobic contacts with L/Y 1.36b (via Y10 P and MeL13 P ), I/V 3.40b (via Y1 P ), W 5.36b (via G4 P ), L 7.39b and I/L 7.43b (via Aib2 P )

Using a vial past its recommended storage period does not change the concentration per se, but degraded semaglutide delivers less active medication than the label concentration suggests

The third option is where the potential for danger lies